Skin Cancer - Risk for melanoma could be estimated by DNA mutation count
Can't see this email? View it online
   
  Skin Cancer  
  The latest skin cancer news from News Medical  
 DermaSensors: The Future of Skin Cancer DetectionDermaSensors: The Future of Skin Cancer Detection
 
The DermaSensor device is a revolutionary, non-invasive and spectroscopy-based tool that can assist clinicians in early skin cancer diagnosis.
 
   Risk for melanoma could be estimated by DNA mutation countRisk for melanoma could be estimated by DNA mutation count
 
Risk for melanoma, the most deadly skin cancer, can be estimated long before detection of any suspicious moles, according to a UC San Francisco scientist who led a new study to detect DNA mutations in individual skin cells.
 
   Skin cancer has increased significantly in the last four decadesSkin cancer has increased significantly in the last four decades
 
Incidence rates of skin cancer (cutaneous malignant melanoma) have increased more than 550% in males and 250% in females since the early 1980s in England - according to a new study by Brighton and Sussex Medical School (BSMS).
 
 Study findings may help identify new targets to inhibit spread of melanoma
 
Study findings may help identify new targets to inhibit spread of melanomaResearch led by Queen Mary University of London has revealed novel insights into the mechanisms employed by melanoma cells to form tumors at secondary sites around the body.
 
 
 Key blood marker can lead to effective melanoma treatments
 
Key blood marker can lead to effective melanoma treatmentsAn Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.
 
 
 Experts caution against routine use of current GEP tests for melanoma patients
 
Experts caution against routine use of current GEP tests for melanoma patientsA consensus statement published today in JAMA Dermatology by an international group of melanoma researchers evaluates the use of prognostic genetic expression profile (GEP) testing to guide clinical management of patients with melanoma.